OBJECTIVES: To identify and describe randomised controlled trials on HIV and AIDS conducted in Africa and to map their spatial distribution using exact geographic coordinates. DESIGN: Construction and analysis of a database of trials conducted wholly or partly in Africa and reported before 2004. DATA SOURCES: CENTRAL, Medline, Embase, and LILACS. RESULTS: Our comprehensive search yielded 284 distinct records that were potentially eligible for inclusion in the database. Of these, 150 articles reported on 77 eligible trials published or reported from 1987 to 2003. Seven trials were identified exclusively from the CENTRAL database. Trials were conducted in 18 of 48 countries in sub-Saharan Africa. None were conducted in north Africa. Only 19 had a principal investigator located in an African country. Forty two trials assessed prevention and 35 assessed treatment. Most studies were funded by government agencies outside Africa (n = 43), with the pharmaceutical industry providing partial support to 16 of these. The pharmaceutical industry provided full or partial support to a further 18 trials. Only 43 trials reported conducting a power calculation for determining sample size. There was no mention of ethical approval or informed consent in 19 and 17 trials, respectively. CONCLUSION: The relatively small number of HIV/AIDS trials conducted in Africa is not commensurate with the burden of disease. Geographical mapping as an adjunct to prospective trial registration is a useful tool for researchers and decision makers to track existing and future trials.
OBJECTIVES: To identify and describe randomised controlled trials on HIV and AIDS conducted in Africa and to map their spatial distribution using exact geographic coordinates. DESIGN: Construction and analysis of a database of trials conducted wholly or partly in Africa and reported before 2004. DATA SOURCES: CENTRAL, Medline, Embase, and LILACS. RESULTS: Our comprehensive search yielded 284 distinct records that were potentially eligible for inclusion in the database. Of these, 150 articles reported on 77 eligible trials published or reported from 1987 to 2003. Seven trials were identified exclusively from the CENTRAL database. Trials were conducted in 18 of 48 countries in sub-Saharan Africa. None were conducted in north Africa. Only 19 had a principal investigator located in an African country. Forty two trials assessed prevention and 35 assessed treatment. Most studies were funded by government agencies outside Africa (n = 43), with the pharmaceutical industry providing partial support to 16 of these. The pharmaceutical industry provided full or partial support to a further 18 trials. Only 43 trials reported conducting a power calculation for determining sample size. There was no mention of ethical approval or informed consent in 19 and 17 trials, respectively. CONCLUSION: The relatively small number of HIV/AIDS trials conducted in Africa is not commensurate with the burden of disease. Geographical mapping as an adjunct to prospective trial registration is a useful tool for researchers and decision makers to track existing and future trials.
Authors: Catherine De Angelis; Jeffrey M Drazen; Frank A Frizelle; Charlotte Haug; John Hoey; Richard Horton; Sheldon Kotzin; Christine Laine; Ana Marusic; A John P M Overbeke; Torben V Schroeder; Hal C Sox; Martin B Van Der Weyden Journal: Lancet Date: 2004 Sep 11-17 Impact factor: 79.321
Authors: Mohit Bhandari; Jason W Busse; Dianne Jackowski; Victor M Montori; Holger Schünemann; Sheila Sprague; Derek Mears; Emil H Schemitsch; Dianne Heels-Ansdell; P J Devereaux Journal: CMAJ Date: 2004-02-17 Impact factor: 8.262
Authors: P J Devereaux; Peter T-L Choi; Samer El-Dika; Mohit Bhandari; Victor M Montori; Holger J Schünemann; Amit X Garg; Jason W Busse; Diane Heels-Ansdell; William A Ghali; Braden J Manns; Gordon H Guyatt Journal: J Clin Epidemiol Date: 2004-12 Impact factor: 6.437
Authors: A Kamali; M Quigley; J Nakiyingi; J Kinsman; J Kengeya-Kayondo; R Gopal; A Ojwiya; P Hughes; L M Carpenter; J Whitworth Journal: Lancet Date: 2003-02-22 Impact factor: 79.321
Authors: J Kreiss; E Ngugi; K Holmes; J Ndinya-Achola; P Waiyaki; P L Roberts; I Ruminjo; R Sajabi; J Kimata; T R Fleming Journal: JAMA Date: 1992 Jul 22-29 Impact factor: 56.272
Authors: Jane P Messina; Michael Emch; Jeremie Muwonga; Kashamuka Mwandagalirwa; Samuel B Edidi; Nicaise Mama; Augustin Okenge; Steven R Meshnick Journal: Soc Sci Med Date: 2010-08-05 Impact factor: 4.634
Authors: Brian G Williams; James O Lloyd-Smith; Eleanor Gouws; Catherine Hankins; Wayne M Getz; John Hargrove; Isabelle de Zoysa; Christopher Dye; Bertran Auvert Journal: PLoS Med Date: 2006-07 Impact factor: 11.069
Authors: Sameer J Pujari; Krishna M Palipudi; Jeremy Morton; Jay Levinsohn; Steve Litavecz; Michael Green Journal: Online J Public Health Inform Date: 2012-09-14
Authors: David S Lawrence; Tshepo Leeme; Mosepele Mosepele; Thomas S Harrison; Janet Seeley; Joseph N Jarvis Journal: PLoS Negl Trop Dis Date: 2021-05-27